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Effect of implant strategy and Optaflexx administration on feedlot performance
and skeletal muscle β-adrenergic
-adrenergic receptor and insulin-like growth factor I mRNA
abundance
Abstract
Feedlot heifers (1,147) weighing 622 lb were used to evaluate the effects of implant strategy and
Optaflexx administration. Implant treatments included Revalor-200 (R200) at arrival, or Revalor-IH at
arrival and reimplantation with Finaplix-H on day 58 (RF). Optaflexx (200 mg/heifer daily of ractopamineHCl) was fed the last 28 days. Treatments were randomly assigned to 16 pens. After 182 days, heifers
were slaughtered, at which time carcass data were obtained and semimembranosus muscle tissue was
excised for RNA isolation. Optaflexx administration significantly increased average daily gain (0.7 lb/day),
feed efficiency (3%), hot carcass weight (10.5 lb), and ribeye area (0.42 square inches); decreased back
fat thickness; and improved yield grade. There was no significant treatment effect on the expression of
β1-adrenergic receptor (AR) mRNA, but there was a tendency for Optaflexx feeding to increase β2-AR
mRNA concentrations. For β3-AR mRNA, Optaflexx treatment numerically increased β3-AR mRNA in
heifers implanted with R200, but significantly decreased expression in heifers implanted with RF.
Optaflexx also significantly decreased IGF-I mRNA in heifers implanted with RF, but numerically increased
IGF-I mRNA in heifers implanted with R200. This data aids our understanding of the interaction between
steroidal implants and Optaflexx in feedlot heifers. Knowledge about the modes of action of various
growth promotants will aid in designing growth promotion strategies to enhance the efficiency of lean
tissue deposition in feedlot cattle.
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Beef Cattle Research – 2006

EFFECT OF IMPLANT STRATEGY AND OPTAFLEXX1 ADMINISTRATION
ON FEEDLOT PERFORMANCE AND SKELETAL MUSCLE β-ADRENERGIC
RECEPTOR AND INSULIN-LIKE GROWTH FACTOR I mRNA ABUNDANCE
E. K. Sissom, J. P. Hutcheson, D. A. Yates, and B. J. Johnson

derstanding of the interaction between steroidal implants and Optaflexx in feedlot heifers. Knowledge about the modes of action of
various growth promotants will aid in designing growth promotion strategies to enhance
the efficiency of lean tissue deposition in feedlot cattle.

Summary
Feedlot heifers (1,147) weighing 622 lb
were used to evaluate the effects of implant
strategy and Optaflexx administration. Implant treatments included Revalor2-200
(R200) at arrival, or Revalor-IH at arrival and
reimplantation with Finaplix2-H on day 58
(RF). Optaflexx (200 mg/heifer daily of ractopamine-HCl) was fed the last 28 days.
Treatments were randomly assigned to 16
pens. After 182 days, heifers were slaughtered, at which time carcass data were obtained and semimembranosus muscle tissue
was excised for RNA isolation. Optaflexx
administration significantly increased average
daily gain (0.7 lb/day), feed efficiency (3%),
hot carcass weight (10.5 lb), and ribeye area
(0.42 square inches); decreased back fat thickness; and improved yield grade. There was no
significant treatment effect on the expression
of β1-adrenergic receptor (AR) mRNA, but
there was a tendency for Optaflexx feeding to
increase β2-AR mRNA concentrations. For
β3-AR mRNA, Optaflexx treatment numerically increased β3-AR mRNA in heifers implanted with R200, but significantly decreased
expression in heifers implanted with RF. Optaflexx also significantly decreased IGF-I
mRNA in heifers implanted with RF, but numerically increased IGF-I mRNA in heifers
implanted with R200. This data aids our un-
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Introduction
Optaflexx is an orally active β-agonist
(ractopamine-HCl) approved for use in feedlot
cattle in the United States. It improves average daily gain, feed efficiency, carcass yield
grade, hot carcass weight, and dressing percentage in feedlot steers when administered at
the recommended daily dose of 200 mg/steer
daily for the last 28 to 42 days of the feeding
period. Optaflexx administration has resulted
in more variable results in heifers than in
steers. Optaflexx works through the β-AR;
there are three different subtypes of β-AR
found in cattle, with the β2-AR being the most
abundant in bovine skeletal muscle. Optaflexx
is believed to elicit its response through binding to the β1-AR. Binding to the β-AR leads
to a cascade of events that is eventually followed by an increase in muscle protein synthesis and a decrease in protein degradation,
which leads to an overall increase in lean
tissue deposition.

Optaflexx is a registered trademark of Elanco Animal Health, Indianapolis, IN.
Revalor and Finaplix are registered trademarks of Intervet, Inc.
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complimentary DNA was generated for use in
real-time, quantitative polymerase chain reaction to evaluate the expression of mRNA for
IGF-I, β1-AR, β2-AR, and β3-AR.

Steroidal implants are also used in feedlot
animals to improve average daily gain, feed
efficiency, and total lean tissue deposition.
One of the mechanisms through which increased muscle growth is achieved with implants is through increased production of muscle insulin-like growth factor I (IGF-I). Insulin-like growth factor I is a potent stimulator
of skeletal muscle growth.

Results and Discussion
Optaflexx administration significantly increased average daily gain and feed efficiency
(Table 1). There was also a 10.5 lb increase in
hot carcass weight, an increase in ribeye area,
a decrease in back fat thickness, and improved
yield grades in response to Optaflexx (Table
1). These responses to Optaflexx were similar
to those typically observed for steers, and
were larger than are often observed for heifers. These performance results are significant
in that heifers have not always been observed
to respond as well to the administration of
Optaflexx as steers do. The response to Optaflexx in our study may be related to the implant strategy used.

The purpose of this trial was to investigate
the effect of Optaflexx administration, in combination with implant strategy, on feedlot
heifer performance and the expression of messenger RNA (mRNA) for IGF-I and the three
β-AR subtypes.
Experimental Procedures
One thousand, one hundred forty-seven
heifer calves with an initial weight of 622 lb
were randomly assigned to 16 pens. One of
four treatments was applied to each pen: 1)
initial Revalor-200 (200 mg trenbolone acetate/20 mg estradiol-17β) without or 2) with
Optaflexx (200 mg/heifer daily of ractopamine-HCl), 3) initial Revalor-IH (80 mg trenbolone acetate/8 mg estradiol-17β) and reimplantation (day 58) with Finaplix-H (200
mg trenbolone acetate) without or 4) with Optaflexx (200 mg/heifer daily of ractopamineHCl). Heifers were fed three times daily and
allowed ad libitum access to feed. The finishing diet consisted of 82.7% flaked corn, 5.1%
alfalfa hay, 3.8% choice white grease, 2.5%
cane molasses, and 5.9% of a finisher supplement, on a dry matter basis. Optaflexx was
administered the last 28 days of the trial, and
all heifers received melengestrol acetate (0.5
mg/heifer daily). Heifers were slaughtered
after 182 days on feed, at which time
semimembranosus muscle samples were obtained. For the gene expression work, two
heifers per pen were analyzed. Total RNA
was isolated from muscle samples and reverse
transcribed into complimentary DNA. The

There was no significant effect of treatments on the expression of β1-AR mRNA
(Figure 1); there was a tendency for Optaflexx
feeding to increase β2-AR mRNA (Figure 2).
For the β3-AR mRNA, there was an implant
by Optaflexx interaction, with Optaflexx leading to a numerical increase in β3-AR mRNA
in heifers implanted with R200, but a significant decrease in heifers implanted with RF
(Figure 3). There was also an implant by Optaflexx interaction on IGF-I mRNA, with Optaflexx leading to a significant decrease in
IGF-I mRNA for heifers implanted with RF
but numerical increases in IGF-I mRNA in
heifers implanted with R200 (Figure 4).
The data from our study demonstrate that
Optaflexx can have a positive effect on feedlot
heifer performance and carcass characteristics.
This may be related to the relative pay out of
implants. At the initiation of Optaflexx feeding, the R200 group had been implanted for
154 days and the RF group had been

25

implanted with Finaplix-H for 96 days. Under
these conditions, the potency of both implants
at the time of Optaflexx initiation was likely
negligible.

study also suggest that Optaflexx may increase the expression of the β2-AR, which has
been observed in some other studies performed by our laboratory. The data obtained
from our study can aid in our understanding of
the mechanisms of action of β-agonists used
as growth promotants in the feedlot industry.
It can also help in the understanding of the
potential for interactions between the use of
steroidal implants and β-agonists.
This
knowledge will aid in our ability to improve
efficiency of lean tissue deposition in beef
cattle.

The performance response in our study
was different than some others that have been
unable to detect responses to Optaflexx in
heifers. Those studies often used heifers implanted closer in time to the initiation of Optaflexx feeding. The differences between our
results and those of others could suggest a
possible interaction between implants and
Optaflexx administration. Results of our

Table 1. Effect of implant and Optaflexx on performance and carcass characteristics of
feedlot heifers
Treatment1
Item

RF

RF+OPT

R200

R200+OPT

Pens

4

4

4

4

Number of heifers

274

271

274

272

Starting weight, lb

623

622

622

622

Dry matter intake, lb/day

16.92

16.90

17.19

16.77

Average daily gain, lba

3.04

3.14

3.10

3.14

Feed:gaina

5.56

5.38

5.54

5.35

Hot carcass weight, lba
Ribeye area, square inchesa
12th rib fat, inches

a

Marbling score2

758

771

764

772

14.46

14.84

14.60

15.02

0.49

0.45

0.49

0.46

425

409

406

398

Kidney, pelvic, and heart fat, %

1.97

2.00

2.01

2.03

Calculated final yield gradea

2.61

2.45

2.61

2.43

a

Optaflexx effect, P<0.05.
RF = Revalor-IH initially plus reimplant with Finaplix-H at 58 days, OPT = Optaflexx fed
during final 28 days of trial, R200 = Revalor-200 at trial initiation.
2
400 = Small.
1
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Figure 1. β1-adrenergic receptor mRNA relative abundance in semimembranosus muscle.
RF = Revalor-IH initially plus reimplant with
Finaplix-H at 58 days, OPT = Optaflexx fed during final 28 days of trial, R200 = Revalor-200 at
trial initiation.
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Figure 2. β2-adrenergic receptor mRNA relative abundance in semimembranosus muscle.
RF = Revalor-IH initially plus reimplant with
Finaplix-H at 58 days, OPT = Optaflexx fed during final 28 days of trial, R200 = Revalor-200 at
trial initiation.
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Figure 3. β3-adrenergic receptor mRNA relative abundance in semimembranosus muscle.
Bars not bearing a common letter differ, P<0.05.
RF = Revalor-IH initially plus reimplant with
Finaplix-H at 58 days, OPT = Optaflexx fed during final 28 days of trial, R200 = Revalor-200 at
trial initiation.
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Figure 4. Insulin-like growth factor-I mRNA
relative abundance in semimembranosus muscle. Bars not bearing a common letter differ,
P<0.05. RF = Revalor-IH initially plus reimplant
with Finaplix-H at 58 days, OPT = Optaflexx fed
during final 28 days of trial, R200 = Revalor-200
at trial initiation.
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